Breast cancer (early) - paclitaxel (TA108)
Fast, easy summary view of NICE guidance on 'early and locally advanced breast cancer'
Paclitaxel is not recommended as an option for the adjuvant treatment of women with early node-postive breast cancer.
Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any significant cost implications. Therefore, no costing template has been developed for this appraisal.
Update to guidance
CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal. NICE and the Department of Health are currently reviewing the future position on updating technology appraisals within clinical guidelines, with particular reference to implications for the funding direction on technology appraisals. In the meantime, the technology appraisal guidance remains available and should continue to be followed. The statutory funding direction remains in place for the recommendations contained in the technology appraisal guidance.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: early and locally advanced breast cancer
This page was last updated: 25 June 2012
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.